Key Highlights
- 41.53% is the move in ClearOne, Inc. (NASDAQ:CLRO) in today's session on November 18, 2026, lifting the traded price to USD 8.88 from a calculated prior close of USD 6.27, a calculated USD 2.61 gain.
- 11.86M shares changed hands in ClearOne, Inc. (NASDAQ:CLRO) today, after a gap of 15.04% above the prior close at the open and a further 23.02% move since the open, a calculated opening price near USD 7.22.
- 4.15 USD is the per-unit price of the concurrent public offering tied to the Cortigent and Vivani Medical merger, a closing condition, against a traded price of USD 8.88 today.
- 68,000 USD is the total cash and restricted cash of ClearOne, Inc. (NASDAQ:CLRO) at September 30, 2026, with zero continuing Revenue and a going-concern warning from management and auditors.
What Moved ClearOne, Inc. (NASDAQ:CLRO) in Trading on November 18, 2026 (+USD 2.61, +41.53%)
The traded price of ClearOne, Inc. (NASDAQ:CLRO) in today's session on November 18, 2026 is USD 8.88, a move of +41.53% on Volume of 11.86M shares. The calculated prior close was USD 6.27 (USD 8.88 divided by 1.4153) and the USD move is +USD 2.61. The shares opened 15.04% above the prior close, a calculated USD 7.22, and traded 23.02% above the open. A corroborated market Capitalization and share count were not found.
The Rationale: No Identified Same-Day Catalyst Around the Cortigent Merger for ClearOne, Inc. (NASDAQ:CLRO)
No catalyst for the November 18, 2026 move was identified in published coverage after a targeted search. The nearest dated event is the Nasdaq hearings panel appeal scheduled for November 17, 2026, against the October 8, 2026 determination to delist the company for failing the USD 2.5 million minimum stockholders' Equity requirement; the outcome was not found. The company has operated as a shell since its October 2025 asset sale to Biamp Systems, and on July 1, 2026 it signed a merger agreement with Cortigent and Vivani Medical structured as a reverse recapitalization. Vivani would receive 12.5 million shares, about 82% of the pro forma company before the financing, and holders of 61% of the voting power approved the share issuance. As general context, shell companies with pending mergers can trade sharply on deal headlines.
Valuation, Liquidity and Risks for ClearOne, Inc. (NASDAQ:CLRO)
The latest reported period is the third quarter of 2026. Continuing operations generated zero revenue, nine-month operating cash outflow was USD 3.4 million, and Working Capital was a USD 663,000 Deficit versus a USD 209,000 surplus at December 31, 2025. Cash was USD 18,000 plus USD 50,000 restricted. Related-party Debt to First Finance, a holder of about 61%, is a USD 1.0 million Facility at 11% maturing December 30, 2026 plus a USD 200,000 advance. The traded USD 8.88 is about 2.14 times the USD 4.15 unit price (calculated). Risks include going-concern language, delisting, merger conditions and dilution from up to 3.6 million financing units. No Market Value was corroborated, so shares should be treated as high-risk and volatile.
Where Things Stand
ClearOne, Inc. (NASDAQ:CLRO) traded at USD 8.88 today, November 18, 2026, up 41.53% from a calculated prior close of USD 6.27, on volume of 11.86M shares. No catalyst was identified in published coverage. The company is a shell with zero revenue, USD 68,000 of cash, a Nasdaq delisting determination dated October 8, 2026 and a pending merger with Cortigent and Vivani Medical. The USD 4.15 financing unit price sits well below today's trading level, and the company is a going-concern risk. Moves of this size can reverse quickly, and this article is not Investment advice.





Please wait processing your request...